Moexipril
- Generic Name
- Moexipril
- Brand Names
- Univasc
- Drug Type
- Small Molecule
- Chemical Formula
- C27H34N2O7
- CAS Number
- 103775-10-6
- Unique Ingredient Identifier
- WT87C52TJZ
- Background
Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.
- Indication
用于治疗高血压。
- Associated Conditions
- Hypertension
A Relative Bioavailability Study of Moexipril HCl 15 mg Tablets Under Fasting Conditions
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-10-09
- Last Posted Date
- 2013-09-26
- Lead Sponsor
- Paddock Laboratories, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00992862
- Locations
- 🇺🇸
Novum Pharmaceutical Research Services, Pittsburg, Pennsylvania, United States
A Study to Compare the Relative Bioavailability of Moexipril HCl/Hydrochlorothiazide in Healthy Adult Volunteers Under Fasting Conditions
- Conditions
- Healthy
- Interventions
- Drug: Uniretic® 15mg/25mg Tablets
- First Posted Date
- 2009-10-06
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Paddock Laboratories, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT00990301
- Locations
- 🇺🇸
Novum Pharmaceutical Research Services, Pittsburg, Pennsylvania, United States
Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions
- Conditions
- Healthy
- Interventions
- Drug: UNIRETIC® 15/25 mg tablets
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 60
- Registration Number
- NCT00834067
- Locations
- 🇺🇸
Gateway Medical Research, Inc., Saint Charles, Missouri, United States
🇺🇸Bioassay Laboratory, Inc., Houston, Texas, United States
Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions
- Conditions
- Healthy
- Interventions
- Drug: UNIRETIC® 15/25 mg tablets
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 60
- Registration Number
- NCT00835042
- Locations
- 🇺🇸
Bioassay Laboratory, Inc., Houston, Texas, United States
🇺🇸Gateway Medical Research, Inc., Saint Charles, Missouri, United States
Moexipril for Primary Biliary Cirrhosis
- First Posted Date
- 2008-01-08
- Last Posted Date
- 2011-05-23
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 20
- Registration Number
- NCT00588302
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.